Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
BSDM's Cash to Debt is ranked higher than
85% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. BSDM: No Debt )
BSDM' s 10-Year Cash to Debt Range
Min: 4.22   Max: No Debt
Current: No Debt

Equity to Asset 0.84
BSDM's Equity to Asset is ranked higher than
88% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. BSDM: 0.84 )
BSDM' s 10-Year Equity to Asset Range
Min: 0.26   Max: 0.97
Current: 0.84

0.26
0.97
Interest Coverage No Debt
BSDM's Interest Coverage is ranked higher than
84% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. BSDM: No Debt )
BSDM' s 10-Year Interest Coverage Range
Min: 16.98   Max: 9999.99
Current: No Debt

16.98
9999.99
F-Score: 3
Z-Score: 6.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -225.24
BSDM's Operating margin (%) is ranked lower than
57% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. BSDM: -225.24 )
BSDM' s 10-Year Operating margin (%) Range
Min: -472.69   Max: 30.78
Current: -225.24

-472.69
30.78
Net-margin (%) -224.67
BSDM's Net-margin (%) is ranked lower than
57% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. BSDM: -224.67 )
BSDM' s 10-Year Net-margin (%) Range
Min: -471.37   Max: 515.82
Current: -224.67

-471.37
515.82
ROE (%) -67.95
BSDM's ROE (%) is ranked lower than
57% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. BSDM: -67.95 )
BSDM' s 10-Year ROE (%) Range
Min: -302.08   Max: 110.18
Current: -67.95

-302.08
110.18
ROA (%) -57.55
BSDM's ROA (%) is ranked lower than
57% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. BSDM: -57.55 )
BSDM' s 10-Year ROA (%) Range
Min: -88.55   Max: 71.65
Current: -57.55

-88.55
71.65
ROC (Joel Greenblatt) (%) -301.27
BSDM's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. BSDM: -301.27 )
BSDM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -537.87   Max: 82.04
Current: -301.27

-537.87
82.04
Revenue Growth (%) 19.70
BSDM's Revenue Growth (%) is ranked higher than
92% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. BSDM: 19.70 )
BSDM' s 10-Year Revenue Growth (%) Range
Min: -35.6   Max: 55.4
Current: 19.7

-35.6
55.4
EBITDA Growth (%) -6.70
BSDM's EBITDA Growth (%) is ranked higher than
71% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. BSDM: -6.70 )
BSDM' s 10-Year EBITDA Growth (%) Range
Min: -30.7   Max: 94.3
Current: -6.7

-30.7
94.3
EPS Growth (%) -6.70
BSDM's EPS Growth (%) is ranked higher than
67% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. BSDM: -6.70 )
BSDM' s 10-Year EPS Growth (%) Range
Min: 0   Max: 26
Current: -6.7

0
26
» BSDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with BSDM



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.70
BSDM's P/B is ranked higher than
52% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. BSDM: 3.70 )
BSDM' s 10-Year P/B Range
Min: 1.9   Max: 46
Current: 3.7

1.9
46
P/S 7.70
BSDM's P/S is ranked lower than
76% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. BSDM: 7.70 )
BSDM' s 10-Year P/S Range
Min: 2.81   Max: 87.88
Current: 7.7

2.81
87.88
EV-to-EBIT 250.00
BSDM's EV-to-EBIT is ranked lower than
78% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. BSDM: 250.00 )
BSDM' s 10-Year EV-to-EBIT Range
Min: 110.1   Max: 1856.9
Current: 250

110.1
1856.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.40
BSDM's Price/Net Cash is ranked higher than
68% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. BSDM: 7.40 )
BSDM' s 10-Year Price/Net Cash Range
Min: 3.04   Max: 87.5
Current: 7.4

3.04
87.5
Price/Net Current Asset Value 5.20
BSDM's Price/Net Current Asset Value is ranked higher than
76% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. BSDM: 5.20 )
BSDM' s 10-Year Price/Net Current Asset Value Range
Min: 2.92   Max: 256.2
Current: 5.2

2.92
256.2
Price/Tangible Book 3.70
BSDM's Price/Tangible Book is ranked higher than
61% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. BSDM: 3.70 )
BSDM' s 10-Year Price/Tangible Book Range
Min: 2.5   Max: 42.7
Current: 3.7

2.5
42.7
Price/Median PS Value 0.40
BSDM's Price/Median PS Value is ranked higher than
98% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. BSDM: 0.40 )
BSDM' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 5.45
Current: 0.4

0.12
5.45
Earnings Yield (Greenblatt) 0.40
BSDM's Earnings Yield (Greenblatt) is ranked lower than
67% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. BSDM: 0.40 )
BSDM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 0.9
Current: 0.4

0.1
0.9
Forward Rate of Return (Yacktman) -15.72
BSDM's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. BSDM: -15.72 )
BSDM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 42.8   Max: 363.1
Current: -15.72

42.8
363.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:BZD.Germany
BSD Medical Corporation was originally incorporated under the laws of the State of Utah on March 17, 1978. On July 3, 1986, the Company was reincorporated in the State of Delaware The Company develops, manufactures, markets, and services medical systems that deliver precision-focused radio frequency (RF) or microwave energy into diseased sites of the body, heating them to specified temperatures as required by a medical therapies. Its product line for cancer therapy has been created to offer hospitals and clinics a complete solution for thermal treatment of cancer as provided through microwave/RF systems. Microwave ablation system is to be used to ablate (remove or vaporize) soft tissue with heat alone. Thermal ablation is used to destroy local tumors using a short intense focus of heat on a specific area, which is usually small, similar to surgical removal of the tumor. Its product line includes systems that have been strategically designed to offer a range of thermal treatment systems for the treatment of cancer, including both hyperthermia and ablation treatment systems. One of its important contributions to the advancement of medical therapy has been its pioneering work in developing a new treatment for conditions associated with enlargement of the prostate that afflicts most men as they age. Some cancers, such as certain cancers of the liver, prostate, kidney, bone metastases and lung cancer, are treated using heat alone to deliver thermal ablation. BSD-500 is used to treat cancers located near the surface of the body, or areas that could be accessed using inserted antennae. The BSD-500 comes in several versions, depending on the customer requirements. The BSD-2000 is used to non-invasively treat deep cancers. This system also comes in several versions, including models with three dimensional, or 3D, steering of electromagnetic energy, as well as the ability to be integrated with MRI. Through research funded by the National Cancer Institute in the United States and supportive efforts by other domestic and international research institutions, the Company enhanced the BSD-2000 to create the new BSD-2000/3D. The BSD-2000/3D adds three-dimensional steering of deep focused energy, as opposed to the two-dimensional steering of energy available in the BSD-2000, delivering even more precise heating of the tumor. Using sophisticated microwave filtering and imaging software, the BSD-2000/3D/MR allows an MRI system to be interfaced with and operate simultaneously with a BSD-2000/3D. Its target customers include clinics, hospitals and institutions in which cancer is treated, located either in the United States or international markets. The company generally provides a 12-month warranty and record a liability for the warranty following installation on all cancer treatment systems and a 90-day limited warranty on individual components. Competitors in the thermal ablation market include RadioTherapeutics, a division of Boston Scientific Cor

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide